Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis

Why a New Campaign Matters

Bronchiectasis affects an estimated 1.5 million adults in the United States, yet many patients experience a delay of 5 years or more before receiving a correct diagnosis. The condition is often confused with chronic bronchitis, COPD, or asthma, leading to inappropriate treatment and a reduced quality of life.

Insmed and Ty Pennington Join Forces

Pharmaceutical leader Insmed, known for its focus on rare lung diseases, announced a partnership with home‑improvement star Ty Pennington to launch a multi‑channel awareness campaign. The initiative aims to:

• Educate the public about the signs and symptoms of bronchiectasis.
• Encourage individuals with chronic cough, frequent infections, or excess mucus to seek a specialist evaluation.
• Provide clinicians with updated diagnostic guidelines and screening tools.

Key Campaign Elements

1. Television & Digital Spots – Short videos featuring Ty discussing his own experience with a family member’s diagnosis, highlighting the importance of early detection.
2. Social Media Challenge – #BreatheClear challenge encourages users to share short clips of “clean‑air” moments while learning a quick symptom checklist.
3. Physician Toolkit – Free downloadable resources, including a symptom‑quiz, CT‑scan interpretation guide, and a referral checklist for primary‑care doctors.
4. Community Webinars – Live Q&A sessions with pulmonologists, patient advocates, and Ty Pennington, streamed on YouTube and Facebook.

What Can Patients Do Right Now?

Even before the campaign fully rolls out, anyone who suspects bronchiectasis should consider the following steps:

• Track cough frequency, sputum volume, and any changes in color.
• Note recurrent chest infections or need for antibiotics.
• Ask a doctor about a high‑resolution CT scan if symptoms persist for more than six months.
• Explore reputable patient‑support groups for evidence‑based information.

Impact Expected

Insmed projects a 20 % increase in early‑stage diagnoses within the first year of the campaign. Early detection not only improves lung function preservation but also expands the pool of patients who may benefit from emerging therapies, including Insmed’s next‑generation inhaled antibiotics.

Conclusion

The partnership between Insmed and Ty Pennington blends medical expertise with mainstream reach, creating a powerful platform to demystify bronchiectasis. By spotlighting symptoms, providing clear diagnostic pathways, and fostering community dialogue, the campaign promises to shorten diagnostic delays and empower patients to take control of their lung health.